The medication Polo (Felodipine extended-release) is commonly used in the treatment of hypertension (high blood pressure). This therapy is generally applied in clinical situations marked by chronically elevated blood pressure, which is the primary condition it treats. Polo provides supportive therapeutic benefit and is used for managing sustained arterial tension, contributing to easing the overall symptom load and helping maintain functional stability, which may assist with maintaining general well-being during symptomatic phases.

This therapy is also considered relevant in contexts involving ischemic heart disease, specifically supporting the management of the symptom of chest pain and tightness (chronic stable angina). Specifically, the medication is applied for addressing conditions involving sustained high blood pressure and the symptoms of chronic stable angina. For patients dealing with chest discomfort, the symptomatic support provided may assist with managing the frequency and intensity of anginal episodes, and assists with maintaining functional stability.

---

Quick Fact: Support for Sustained Arterial Tension This medication is commonly used to help manage the overall symptom load associated with mild-to-moderate chronic hypertension and to provide supportive relief when symptoms of stable angina interfere with routine activities.

Who Can and Cannot Use Polo?

Eligibility for Polo (Felodipine extended-release tablets) is strictly defined by regulatory health authorities and is based on a patient's age, physiological status, and underlying health conditions.

Contraindicated Populations (Must Not Use)

Use is contraindicated in patients with a known hypersensitivity or allergy to Felodipine or any component of the formulation. Absolute prohibitions also apply to patients with uncompensated heart failure, unstable angina pectoris, or a history of recent acute myocardial infarction. Specific conditions such as severe hepatic impairment and certain cardiac outflow obstructions also serve as regulatory contraindications.

Age and Physiological Restrictions

The medicine is intended for the adult population (aged 18 and over). Safety and efficacy have not been established in the pediatric population, and use in children is generally not recommended. Polo is contraindicated during pregnancy and is not recommended for use by women who are breastfeeding.

Conditional Use

Geriatric patients (65 and older) and patients with mild-to-moderate hepatic impairment require caution, and treatment is typically initiated with a lower dose due to altered drug clearance. Dosage adjustment is generally not required for patients with renal impairment.

Interactions with other medicines and products

Polo (Felodipine extended-release) has an official interaction profile defined primarily by how other substances modify its systemic plasma exposure. Felodipine is metabolized by the Cytochrome P450 3A4 (CYP3A4) enzyme, making it highly susceptible to pharmacokinetic interactions.

Exposure Modification: Medicines classified as potent CYP3A4 inhibitors, such as Itraconazole and Erythromycin, significantly increase Felodipine’s systemic concentration (AUC and Cmax). Itraconazole, for instance, is documented to cause an approximately eight-fold increase in Felodipine exposure. Conversely, potent CYP3A4 inducers like the anticonvulsants Carbamazepine and Phenytoin, or the antibiotic Rifampin, can substantially decrease Felodipine concentrations, potentially leading to levels below the necessary therapeutic range.

Substance and Food Restrictions: Co-administration with the herbal product St. John's wort is restricted as it acts as a CYP3A4 inducer. In the food-substance category, the ingestion of Grapefruit Juice is advised against because it significantly increases Felodipine’s oral bioavailability; this restriction is due to the unpredictable and pronounced increase in drug exposure.

Other Interaction Notes: When co-administered with other antihypertensive agents, an additive pharmacodynamic effect may occur, reinforcing the blood pressure-lowering action. Additionally, the plasma concentration of the immunosuppressant Tacrolimus is formally documented to be increased by Felodipine. Clearance of Felodipine is also reduced in patients with hepatic dysfunction, which is a population-specific constraint resulting in elevated plasma concentrations.

Targeted Molecular Action: Blocking Calcium Influx

The action of Polo (Felodipine) begins with the selective inhibition of Voltage-Gated L-Type Calcium Channels in the walls of small peripheral arteries. This molecular blockade prevents the influx of extracellular calcium ions (Ca^2+) into the smooth muscle cells, which are required for initiating cellular contraction.

Cascade Effect: Reducing Arterial Resistance

By limiting intracellular calcium, the drug disrupts the muscle contraction sequence that controls arterial tone. This mechanistic cascade leads directly to the relaxation and widening of the arteriolar smooth muscle (vasodilation). This action reduces the overall impedance to blood flow throughout the body, resulting in a direct lowering of Peripheral Vascular Resistance (PVR).

Physiological Constraint: The Baroreceptor Reflex

The peripheral vasodilation caused by the drug's mechanism can trigger a homeostatic counter-regulatory response known as the Baroreceptor Reflex. This action involves the sympathetic nervous system increasing its activity, which partially counteracts the systemic reduction of resistance.

How to Use Polo: Official Administration Guidelines

Polo (Felodipine) is formulated as an extended-release (ER) tablet for oral administration, designed to provide a sustained therapeutic effect over 24 hours. The primary principle governing its use is the once-daily frequency, which supports long-term management of chronic conditions. The official usage protocol mandates strict adherence to the tablet's integrity and specific timing conditions.

---

Official Dosing Regimen

The standard starting dose for adult patients is typically 5 mg once daily. However, dosage must be established based on specific therapeutic needs and official labeling. The maintenance dose ranges from 2.5 mg to 10 mg once daily, and the maximum recommended dose is 10 mg daily. Dose adjustments, if necessary, should be implemented gradually, generally at intervals of at least two weeks.

---

Administration and Handling

Procedural Instruction	Context and Guidelines
Route and Form	Must be taken orally as an extended-release tablet.
Tablet Integrity	The tablet must be swallowed whole and must not be cut, crushed, or chewed to preserve its slow-release characteristics.
Timing with Food	Should be taken without food or with a light, low-fat meal.
Dietary Restriction	Consumption of grapefruit or grapefruit juice must be avoided.
Missed Dose	If a dose is missed, it should be skipped, and the next scheduled dose should be taken at the regular time; do not double the dose.

---

Population-Specific Use

Official instructions stipulate that an initial dose of 2.5 mg once daily is advised for specific populations, including older adults and patients with hepatic (liver) impairment. This lower starting dose accounts for the potential for altered drug processing in these groups. For patients with renal impairment, no dose adjustment is typically required.

Polo: Recent Clinical Evidence

This section summarizes the types of official research—including randomized trials and outcome studies—that evaluated Felodipine extended-release (Polo) in clinical settings, focusing on what the studies measured and which populations they involved. Studies help show what has been observed so far, but research provides context and describes group patterns, not personal outcomes.

Evidence for Use in Managing High Blood Pressure (Hypertension)

Research examining Polo for high blood pressure is supported by a body of evidence including randomized controlled trials (RCTs) and long-term outcome studies. These trials primarily measured changes in key markers, specifically the change in Systolic and Diastolic Blood Pressure (SBP and DBP) over periods typically ranging from 4 to 12 weeks. Research in long-term studies also monitored associations with major events, such as stroke, over follow-up durations averaging 3 to 4 years. Research also explored patterns of change in surrogate markers, such as Left Ventricular Hypertrophy (LVH).

Evidence for Use in Chronic Stable Angina

The research exploring Polo's role in the management of exercise-induced chest pain (chronic stable angina) includes randomized, double-blind trials. These short-term studies, often lasting 5 to 12 weeks, focused on outcomes related to physical discomfort and daily functioning or activity level. Studies explored functional measures, such as Total Exercise Time, and monitored patient-reported outcomes describing perceived discomfort, including the frequency of anginal attacks. Research exploring long-term effects on the reduction of major cardiac events specifically for this indication is more limited.

Evidence Gaps and Areas of Scientific Uncertainty

The most comprehensive long-term outcome data were observed when Felodipine was used in combination therapy with other blood pressure medicines. This can make the isolated long-term monotherapy outcome profile a known limitation of the research design. While studies have focused on older adults with high blood pressure, data for other groups, such as pediatric populations or those with multiple complex coexisting conditions, remains insufficient.

Common questions about Polo (FAQ)

Q: Is Polo the same type of medicine as [similar competing drug name]?

According to the official product information, Polo contains the active ingredient Felodipine, which is classified as a dihydropyridine class of calcium channel blockers (CCBs). This classification defines its specific mechanism, which works by relaxing peripheral blood vessels to help lower blood pressure. While many medicines treat the same conditions, the specific class determines how the drug works.

Q: How quickly should I expect to see an effect from Polo?

Regulatory documents indicate that Polo is an extended-release (long-acting) tablet, meaning the active ingredient is released slowly over time. Following administration, an initial reduction in blood pressure generally occurs within two to five hours. This medication is intended for chronic, long-term management rather than immediate relief.

Q: Are all listed side effects of Polo considered common?

No, official adverse reaction information categorizes side effects based on how frequently they were observed in clinical trials. These categories include Very Common (most frequent), Common (frequently observed), Uncommon, Rare, and Very Rare. Therefore, not every potential effect listed in the full product information is one that is commonly expected by patients.

Q: What is the difference between the active ingredient and the inactive ingredients in Polo?

The active ingredient, Felodipine, is the component that produces the intended medical effect, such as lowering blood pressure. Inactive ingredients (excipients) are necessary components used to form the extended-release tablet and do not provide therapeutic action themselves. These inactive ingredients are vital for controlling the drug's slow, sustained release.

Q: What should I do if I experience a severe or allergic reaction to Polo?

Official patient information describes that symptoms of a severe reaction, such as swelling of the face or tongue, or signs of dangerously low blood pressure like feeling faint or dizzy, are serious adverse events. Regulatory warnings state that emergency services should be contacted if serious adverse events are experienced.

Q: Is Polo effective for everyone who uses it?

Clinical trials and official information describe the average response and group patterns of effectiveness observed in studied populations. As with most medicines, an individual patient's response can vary. Achieving the desired effect may involve adjustments to the treatment plan, which is managed by a healthcare provider.

Q: Are there any specific lifestyle changes mentioned in official documents to go along with Polo use?

Official guidelines recommend taking the medicine without food or with a light, low-fat meal to ensure proper absorption. Additionally, official regulatory warnings strictly advise that grapefruit or grapefruit juice must be completely avoided due to the risk of a harmful drug interaction.

Q: Does Polo cause drowsiness?

The official safety profile commonly lists central nervous system effects such as dizziness and fatigue as potential side effects. The more specific term somnolence (drowsiness) has also been reported in regulatory documents, although it is often classified as an uncommon effect.

Q: Can a patient stop taking Polo once their symptoms improve?

Since Polo is used for chronic conditions, stopping the medicine abruptly is often advised against. Regulatory documents state that any change to the treatment plan must be discussed with a healthcare professional, as stopping treatment may cause the underlying condition to return or worsen.

Q: What is the risk of dependence or addiction associated with Polo?

According to official regulatory bodies, including the U.S. Drug Enforcement Administration (DEA) and international equivalents, the active ingredient Felodipine is not classified as a controlled substance. This designation indicates that the risk of dependence or abuse is considered low.

Q: Can Polo affect my ability to drive or operate machinery?

Official documents state that the medicine may have a minor or moderate influence on the ability to drive or use heavy machinery. The label notes that caution is advised if side effects such as headache, dizziness, or fatigue are experienced, as these effects may impact the ability to drive or operate machinery.

Q: Is there a generic version of Polo available?

Yes, regulatory product catalogs confirm that the active ingredient, Felodipine, is widely available as a generic extended-release tablet in various countries. Generic versions contain the same active ingredient and meet the regulatory quality standards established for the medication.

Q: Do the side effects of Polo usually go away after a few weeks?

Official safety summaries indicate that some common side effects, such as flushing (reddening of the skin), headache, and dizziness, often occur when treatment is started or when the dose is changed. These reactions are typically transient (temporary) and tend to diminish with time.

Q: How does alcohol interact with Polo?

Official patient information notes that alcohol consumption may have additive effects in lowering blood pressure when combined with Polo. This combination can increase the risk of experiencing certain side effects, such as dizziness, lightheadedness, or fainting. Official documentation advises that alcohol consumption should be avoided or limited.

Q: Is there a risk of withdrawal symptoms if Polo is stopped suddenly?

While regulatory documents do not definitively categorize a withdrawal syndrome, for chronic conditions like high blood pressure, stopping the drug abruptly is often advised against. The main concern is that the underlying symptoms the medicine was treating may return or worsen rapidly.

Q: What does 'use with caution' mean for certain interactions with Polo?

In regulatory documents, the classification 'use with caution' generally implies that a drug or substance interaction is considered moderately clinically significant. This implies the drug may still be used, but it generally requires clinical oversight to manage potential risks.

Q: Does taking Polo require regular monitoring or blood tests?

Official guidelines recommend routine monitoring of the patient's blood pressure response and checking for signs of swelling (peripheral edema). Additionally, liver function may need to be monitored in patients who have pre-existing hepatic impairment.

Q: Does Polo interact with common over-the-counter pain relievers?

Official drug interaction databases indicate that some non-steroidal anti-inflammatory drugs (NSAIDs, such as ibuprofen) may have the potential to reduce the blood pressure-lowering effect of Felodipine. The combined use may warrant monitoring of blood pressure, depending on clinical judgment.

Q: What happens if I accidentally take more Polo than intended?

Official regulatory warnings state that taking an overdose can cause a significant lowering of blood pressure and, in some cases, a rapid or irregular heart rate. Severe hypotension (very low blood pressure) can be life-threatening. Official regulatory warnings state that immediate medical attention is necessary in the event of an overdose.

Q: What is the official safety classification of Polo?

Polo (Felodipine) is classified as a prescription-only medicine, meaning it requires authorization from a licensed provider. It also has specific restrictions; for example, official documents state the medication is Contraindicated during Pregnancy.

Q: Is it possible for Polo to cause weight gain or loss?

Official documents list rapid weight gain and unusual weight gain or loss as uncommon or less common side effects. It is also noted that fluid retention, particularly in the ankles and feet (peripheral edema), is a common, dose-dependent side effect that may contribute to changes in body weight.

Q: What is the maximum duration of treatment with Polo as officially defined?

Official prescribing information states that the medicine is indicated for the long-term management of chronic conditions. Because of this intended use for sustained control, the official label does not generally define a specific maximum duration of treatment.

Q: Is Polo considered a controlled substance?

No, official regulatory scheduling confirms that Polo, which contains the active ingredient Felodipine, is not designated as a controlled substance by the U.S. Drug Enforcement Administration or equivalent international agencies.

Q: How is the safety of Polo monitored after it's approved for use?

The safety of Polo is continuously monitored through post-marketing surveillance systems used by regulatory agencies. This includes a system where healthcare professionals and patients can report any suspected adverse reactions to the relevant government bodies (e.g., the MHRA Yellow Card Scheme).

Q: What is the purpose of the black box warning on Polo, if applicable?

Official labeling for Polo (Felodipine) does not contain a Black Box Warning. A Black Box Warning is the U.S. Food and Drug Administration's (FDA) most stringent warning, used to highlight potentially serious or life-threatening risks.

How to Store and Dispose of Polo (Felodipine Extended-Release Tablets)

Official regulatory guidelines define strict conditions to maintain the stability and safety of Polo (Felodipine extended-release).

Storage Requirements

The tablets must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), with limited excursions permitted. It is mandatory to store the medication in its original, tightly closed, light-resistant container to ensure protection from both moisture and light. As a critical safety measure, Polo must be kept out of the reach and sight of children at all times.

Disposal Instructions

To dispose of unused or expired tablets, the primary recommended method is utilizing a formal drug take-back program. If a take-back program is unavailable, the medicine must be removed from its container, mixed with an undesirable substance (such as coffee grounds or dirt), sealed in a plastic bag, and then discarded with household trash. Do not flush the tablets down the toilet or sink.